Investment Analysts’ Weekly Ratings Changes for Arcutis Biotherapeutics (ARQT)

A number of firms have modified their ratings and price targets on shares of Arcutis Biotherapeutics (NASDAQ: ARQT) recently:

• 12/29/2025 – Arcutis Biotherapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/29/2025 – Arcutis Biotherapeutics was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating.
• 12/27/2025 – Arcutis Biotherapeutics was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 12/22/2025 – Arcutis Biotherapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – Arcutis Biotherapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/14/2025 – Arcutis Biotherapeutics was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 12/8/2025 – Arcutis Biotherapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/6/2025 – Arcutis Biotherapeutics was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 12/1/2025 – Arcutis Biotherapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/28/2025 – Arcutis Biotherapeutics had its price target raised by analysts at Mizuho from $32.00 to $37.00. They now have an “outperform” rating on the stock.

Insider Activity at Arcutis Biotherapeutics

In related news, insider Patrick Burnett sold 17,250 shares of the business’s stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $24.18, for a total transaction of $417,105.00. Following the completion of the sale, the insider owned 98,325 shares of the company’s stock, valued at $2,377,498.50. This represents a 14.93% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Larry Todd Edwards sold 29,131 shares of the stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $25.16, for a total value of $732,935.96. Following the sale, the insider owned 150,193 shares in the company, valued at $3,778,855.88. The trade was a 16.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 279,725 shares of company stock valued at $7,473,992 over the last 90 days. Corporate insiders own 9.40% of the company’s stock.

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.